Holen Sie sich die Stockscreener-App
34.68
1.08%
0.37
Handel nachbörslich:
34.68
Ideaya Biosciences Inc Aktie (IDYA) Neueste Nachrichten
Fisher Asset Management LLC Lowers Stock Holdings in IDEAYA Biosciences, Inc. $IDYA - MarketBeat
IDYA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
IDEAYA Biosciences, Inc. (IDYA) Stock Analysis: A Biotech Gem With 51% Upside Potential - DirectorsTalk Interviews
Ideaya Biosciences Insider Bought Shares Worth $1,647,890, According to a Recent SEC Filing - marketscreener.com
Insider Buying: IDEAYA Biosciences (NASDAQ:IDYA) Director Buys 50,000 Shares of Stock - MarketBeat
Ideaya Biosciences (IDYA) director Stein buys $1.65 million in stock By Investing.com - Investing.com Australia
Ideaya Biosciences (IDYA) director Stein buys $1.65 million in stock - Investing.com
Director Jeffrey Stein buys 50,000 IDEAYA Biosciences (IDYA) shares in market - Stock Titan
IDEAYA Biosciences Director Jeffrey Stein Acquires 50,000 Shares - TradingView
IDEAYA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update - The AI Journal
Assessing IDEAYA Biosciences (IDYA) Valuation After IDE034 First-In-Human Dosing Milestone - Yahoo Finance
Biocytogen Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of IDEAYA's First-in-Class B7H3/PTK7 Bispecific TOP1 ADC IDE034 - lelezard.com
Biocytogen Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of IDEAYA’s First-in-Class B7H3/PTK7 Bispecific TOP1 ADC IDE034 - STT Info
Fifth Lane Capital LP Invests $932,000 in IDEAYA Biosciences, Inc. $IDYA - MarketBeat
Ideaya Biosciences announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Ideaya Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Oncology company IDEAYA grants 346,200 stock options to new hires - Stock Titan
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE034, a Potential First-In-Class B7H3/PTK7 Bispecific Top1 ADC - marketscreener.com
(IDYA) Risk Channels and Responsive Allocation - Stock Traders Daily
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE034, a Potential First-In-Class B7H3/PTK7 Bispecific TOP1 ADC - The AI Journal
Ideaya Biosciences Announces First-Patient-In For Phase 1 Trial Of Ide034, A Potential First-In-Class B7h3/Ptk7 Bispecific Top1 Adc - TradingView
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE034, a Potential First-In-Class B7H3/PTK7 Bispecific TOP1 ADC – Company Announcement - Financial Times
IDEAYA Biosciences, Inc. (IDYA) Stock Analysis: Unlocking A Potential 58% Upside - DirectorsTalk Interviews
Published on: 2026-02-25 12:19:59 - baoquankhu1.vn
Published on: 2026-02-24 09:21:42 - baoquankhu1.vn
IDEAYA Biosciences appoints Theodora Ross as development chief - Investing.com South Africa
IDEAYA Biosciences Teases Late-March Phase III Darovasertib Readout, ADC Updates, New KAT6/7 Phase I Launch - Yahoo Finance
IDYA: Darovasertib's phase 3 PFS readout is imminent, with accelerated approval filing expected this year - TradingView
IDEAYA Biosciences Teases End-of-March Data for Darovasertib Combo at Citi Oncology Summit - Yahoo Finance
Can IDEAYA Biosciences Inc reach all time highs this yearWeekly Stock Analysis & High Accuracy Trade Signal Alerts - baoquankhu1.vn
Theodora Ross Joins Ideaya, Leaving Impact on AbbVie (ABBV) - GuruFocus
Ideaya Biosciences Announces Appointment Of Dr. Theodora (Theo) Ross, M.D., Ph.D., As Chief Development Officer - TradingView
IDEAYA Biosciences Announces Appointment of Dr. Theodora (Theo) Ross, M.D., Ph.D., as Chief Development Officer - PR Newswire
Is IDEAYA Biosciences Inc. forming a breakout patternWeekly Risk Summary & Consistent Growth Equity Picks - mfd.ru
IDEAYA Biosciences, Inc. $IDYA Shares Acquired by Fiera Capital Corp - MarketBeat
What’s the analyst consensus on IDEAYA Biosciences Inc.Earnings Risk Summary & Weekly Stock Breakout Alerts - mfd.ru
Aberdeen Group plc Purchases 116,743 Shares of IDEAYA Biosciences, Inc. $IDYA - MarketBeat
Cantor Fitzgerald reiterates Ideaya Biosciences stock Overweight rating By Investing.com - Investing.com Canada
Cantor Fitzgerald reiterates Ideaya Biosciences stock Overweight rating - Investing.com
Wedbush Adjusts Price Target on IDEAYA Biosciences to $52 From $49, Maintains Outperform Rating - marketscreener.com
IDEAYA Biosciences' (IDYA) "Buy" Rating Reiterated at Guggenheim - MarketBeat
IDEAYA Biosciences, Inc. SEC 10-K Report - TradingView
Published on: 2026-02-17 23:06:22 - mfd.ru
Wedbush Adjusts IDEAYA Biosciences Price Target to $52 From $49, Maintains Outperform Rating - marketscreener.com
Ideaya Biosciences earnings matched, revenue topped estimates By Investing.com - Investing.com Canada
IDEAYA Biosciences Reports Fourth Quarter and Full Year 2025 Fin - GuruFocus
Ideaya Biosciences Q4 Net Loss Narrows as Revenue Rises - marketscreener.com
Earnings Flash (IDYA) IDEAYA Biosciences Posts Q4 Net Loss $0.94 a Share, vs. FactSet Est of $1.05 Loss - marketscreener.com
Earnings Flash (IDYA) IDEAYA Biosciences, Inc. Reports Q4 Revenue $10.9M, vs. FactSet Est of $6.3M - marketscreener.com
IDEAYA Biosciences Q4 Loss Declines - Nasdaq
What is IDEAYA Biosciences Inc. s P E ratio telling usJuly 2025 Trends & Verified Swing Trading Watchlists - mfd.ru
(IDYA) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Is IDEAYA Biosciences Inc. benefiting from innovation trendsJuly 2025 Price Swings & Weekly Stock Breakout Alerts - mfd.ru
Capital Research reports 6% IDEAYA Biosciences (IDYA) ownership stake - Stock Titan
What is IDEAYA Biosciences Inc.’s book value per share2025 EndofYear Setup & Smart Swing Trading Techniques - mfd.ru
IDEAYA Biosciences, Inc. $IDYA Shares Acquired by Candriam S.C.A. - MarketBeat
IDEAYA Biosciences, Inc. (IDYA) Stock Analysis: A 54% Potential Upside in the Precision Medicine Oncology Space - DirectorsTalk Interviews
Citizens reiterates Market Outperform rating on Ideaya Biosciences stock By Investing.com - Investing.com Canada
IDEAYA Biosciences (IDYA) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
IDEAYA Biosciences (IDYA): Unpacking The 46.63% Potential Upside In Precision Oncology - DirectorsTalk Interviews
IDEAYA Biosciences, Inc. $IDYA Shares Acquired by New York State Common Retirement Fund - MarketBeat
Liquidity Mapping Around (IDYA) Price Events - Stock Traders Daily
IDEAYA Biosciences to Participate in Upcoming February 2026 Investor Relations Events - MEXC
Has The Market Overreacted To Recent Weakness In IDEAYA Biosciences (IDYA) Shares? - Yahoo Finance
AlphaQuest LLC Has $1.12 Million Stock Position in IDEAYA Biosciences, Inc. $IDYA - MarketBeat
IDEAYA Biosciences to Participate in Upcoming February 2026 Investor Relations Events – Company Announcement - Financial Times
Institution Moves: Is IDEAYA Biosciences Inc benefiting from innovation trends2025 Support & Resistance & Safe Capital Investment Plans - baoquankhu1.vn
0.11%
6.00%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):